Phosphagenics Sp ADR (PPGNY) 1.8500 $PPGNY
Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising
PR Newswire - Mon Jul 21, 6:00AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$12.2 million of its A$16.3 million capital raising program. The Company is looking to raise an additional A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.
Global Transdermal Drug Delivery Market 2014-2018 with ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen Pharma & Novartis Dominating
M2 - Wed Jul 16, 9:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sz2mh3/global) has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. The Global Transdermal Drug Delivery market will grow at a CAGR of 9.9% Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin. This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: - Smoking Cessation - Pain Management - Hormone Therapy - Cardiovascular Indications - Others Key Vendors - ANI Pharmaceuticals Inc. - Antares Pharma Inc. - Bayer AG - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors - 3M Pharmaceuticals Co. - Durect Corp. - Iontera Inc. - Isis Biopolymer Inc. - LTS Lohmann Therapie-Systeme AG - Mylan Laboratories Inc. - Nitto Denko Corp. - Pantec Biosolutions AG - Phosphagenics Ltd. - Tesa Labtec GmbH - Teva Pharmaceutical Industries Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Competitive Assessment of Transdermal Drugs Delivery Market - Optimisation of Transdermal Drug Delivery - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/sz2mh3/global
ANIP: 53.95 (+2.48), MYL: 54.05 (-0.68), TEVA: 57.07 (-0.10), DRRX: 0.84 (+0.01), ATRS: 2.30 (unch), NVS: 93.95 (-0.43)
Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
REV: 33.18 (-0.38), AVP: 10.07 (-0.19), RDEN: 17.41 (-0.29), DSKX: 0.76 (+0.05), AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), PG: 88.11 (-0.49)
Phosphagenics' A$19.3 million Capital Raising
PR Newswire - Fri Jul 11, 8:30AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders. The placement of A$16.3 million will be made in two tranches.
Phosphagenics to Host Investor Call on Wednesday, April 2nd at 4:00pm EDT (USA)
PR Newswire - Wed Mar 26, 7:00AM CDT
Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY) ("Phosphagenics" or "the Company"
announced today that management will host an investor conference call and webcast to discuss the commercial opportunities arising from a range of innovative analgesic products emerging from the Company's patented TPM® drug delivery technology. The Company will describe how TPM® is enabling it to establish a unique competitive position in the transdermal and topical delivery of diverse analgesics, including oxymorphone and oxycodone. The Company will review current success stories, ongoing and future development plans, and the commercial opportunity for unique and innovative products that overcome the limitations of analgesics currently on market.
'Acne Vulgaris - Pipeline Review, H2 2013' Contains Discovery and Pre-Clinical Stage Products
M2 - Tue Sep 03, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mddqlt/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. Scope - A snapshot of the global therapeutic scenario for Acne Vulgaris. - A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acne Vulgaris pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Normal 0 false false false MicrosoftInternetExplorer4 Advancell AndroScience Corporation AntiCancer, Inc. Ausio Pharmaceuticals, LLC Boehringer Ingelheim GmbH Braintree Laboratories, Inc. Ensoltek Co., Ltd. Foamix Ltd. Galderma S.A. Hygeia Therapeutics, Inc. Lee's Pharmaceutical Holdings Limited Maruho Co.,Ltd. Medicis Pharmaceutical Corporation NanoBio Corporation Phosphagenics Limited Photocure ASA Quest PharmaTech Inc. Toyama Chemical Co. Ltd Valeant Pharmaceuticals International XBiotech USA, Inc. XOMA Ltd. For more information visit http://www.researchandmarkets.com/research/md...ne_vulgari About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VRX.TO: 151.47 (+1.32)
Phosphagenics Signs Research Agreement with the Agricultural Research Service
PR Newswire - Mon May 20, 7:00AM CDT
-- Collaboration with the U.S. Department of Agriculture's (USDA) Agricultural Research Service (ARS) in treatment of mastitis
Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising
PR Newswire - Mon Jul 21, 6:00AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$12.2 million of its A$16.3 million capital raising program. The Company is looking to raise an additional A$3 million from a share purchase plan (SPP) to be offered to existing shareholders.
Global Transdermal Drug Delivery Market 2014-2018 with ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen Pharma & Novartis Dominating
M2 - Wed Jul 16, 9:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sz2mh3/global) has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. The Global Transdermal Drug Delivery market will grow at a CAGR of 9.9% Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin. This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: - Smoking Cessation - Pain Management - Hormone Therapy - Cardiovascular Indications - Others Key Vendors - ANI Pharmaceuticals Inc. - Antares Pharma Inc. - Bayer AG - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors - 3M Pharmaceuticals Co. - Durect Corp. - Iontera Inc. - Isis Biopolymer Inc. - LTS Lohmann Therapie-Systeme AG - Mylan Laboratories Inc. - Nitto Denko Corp. - Pantec Biosolutions AG - Phosphagenics Ltd. - Tesa Labtec GmbH - Teva Pharmaceutical Industries Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Competitive Assessment of Transdermal Drugs Delivery Market - Optimisation of Transdermal Drug Delivery - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/sz2mh3/global
ANIP: 53.95 (+2.48), MYL: 54.05 (-0.68), TEVA: 57.07 (-0.10), DRRX: 0.84 (+0.01), ATRS: 2.30 (unch), NVS: 93.95 (-0.43)
Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
REV: 33.18 (-0.38), AVP: 10.07 (-0.19), RDEN: 17.41 (-0.29), DSKX: 0.76 (+0.05), AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), PG: 88.11 (-0.49)
Phosphagenics' A$19.3 million Capital Raising
PR Newswire - Fri Jul 11, 8:30AM CDT
Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today announced that it has raised A$19.3 million via a placement of A$16.3 million to institutional investors in Europe, the U.S., Asia and Australia and A$3 million from a share purchase plan (SPP) to be offered to existing shareholders. The placement of A$16.3 million will be made in two tranches.
Phosphagenics to Host Investor Call on Wednesday, April 2nd at 4:00pm EDT (USA)
PR Newswire - Wed Mar 26, 7:00AM CDT
Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY) ("Phosphagenics" or "the Company"
announced today that management will host an investor conference call and webcast to discuss the commercial opportunities arising from a range of innovative analgesic products emerging from the Company's patented TPM® drug delivery technology. The Company will describe how TPM® is enabling it to establish a unique competitive position in the transdermal and topical delivery of diverse analgesics, including oxymorphone and oxycodone. The Company will review current success stories, ongoing and future development plans, and the commercial opportunity for unique and innovative products that overcome the limitations of analgesics currently on market. 'Acne Vulgaris - Pipeline Review, H2 2013' Contains Discovery and Pre-Clinical Stage Products
M2 - Tue Sep 03, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mddqlt/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. Scope - A snapshot of the global therapeutic scenario for Acne Vulgaris. - A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acne Vulgaris pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Normal 0 false false false MicrosoftInternetExplorer4 Advancell AndroScience Corporation AntiCancer, Inc. Ausio Pharmaceuticals, LLC Boehringer Ingelheim GmbH Braintree Laboratories, Inc. Ensoltek Co., Ltd. Foamix Ltd. Galderma S.A. Hygeia Therapeutics, Inc. Lee's Pharmaceutical Holdings Limited Maruho Co.,Ltd. Medicis Pharmaceutical Corporation NanoBio Corporation Phosphagenics Limited Photocure ASA Quest PharmaTech Inc. Toyama Chemical Co. Ltd Valeant Pharmaceuticals International XBiotech USA, Inc. XOMA Ltd. For more information visit http://www.researchandmarkets.com/research/md...ne_vulgari About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VRX.TO: 151.47 (+1.32)
Phosphagenics Signs Research Agreement with the Agricultural Research Service
PR Newswire - Mon May 20, 7:00AM CDT
-- Collaboration with the U.S. Department of Agriculture's (USDA) Agricultural Research Service (ARS) in treatment of mastitis
